Literature DB >> 7923871

Cytokine production in varicella zoster virus-stimulated limiting dilution lymphocyte cultures.

Y Zhang1, M Cosyns, M J Levin, A R Hayward.   

Abstract

Human blood lymphocytes were stimulated with varicella zoster virus (VZV) antigen in limiting dilution cultures and the amounts of interferon-gamma (IFN-gamma) and IL-4 measured in the supernatants. The results indicate that up to 85% of proliferating cells of young adults produce IFN-gamma and up to 10% make IL-4. At limiting dilution, few if any wells were positive for both IFN-gamma and IL-4. The amount of IFN-gamma per well increased in the presence of antibody to IL-4, but anti-IFN-gamma not increase IL-4 production. The frequency of wells containing IFN-gamma was lower in subjects < 19 or > 55 years of age, and the amounts of IFN-gamma in positive wells was significantly lower in cultures of the older subjects' lymphocytes. The frequency of IL-4-making cells did not fall significantly with age. The data suggest that the age-related decline in the frequency of blood T cells which responds to VZV affects mainly the cells with a Th1-like cytokine phenotype.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7923871      PMCID: PMC1534160          DOI: 10.1111/j.1365-2249.1994.tb06618.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  27 in total

1.  Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation.

Authors:  R de Waal Malefyt; H Yssel; J E de Vries
Journal:  J Immunol       Date:  1993-06-01       Impact factor: 5.422

2.  Human atopen-specific types 1 and 2 T helper cell clones.

Authors:  E A Wierenga; M Snoek; H M Jansen; J D Bos; R A van Lier; M L Kapsenberg
Journal:  J Immunol       Date:  1991-11-01       Impact factor: 5.422

3.  Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones.

Authors:  P Salgame; J S Abrams; C Clayberger; H Goldstein; J Convit; R L Modlin; B R Bloom
Journal:  Science       Date:  1991-10-11       Impact factor: 47.728

4.  IL-12 induces the production of IFN-gamma by neonatal human CD4 T cells.

Authors:  C Y Wu; C Demeure; M Kiniwa; M Gately; G Delespesse
Journal:  J Immunol       Date:  1993-08-15       Impact factor: 5.422

5.  "Anergy" of TH0 helper T lymphocytes induces downregulation of TH1 characteristics and a transition to a TH2-like phenotype.

Authors:  T F Gajewski; D W Lancki; R Stack; F W Fitch
Journal:  J Exp Med       Date:  1994-02-01       Impact factor: 14.307

6.  IL-10 is produced by subsets of human CD4+ T cell clones and peripheral blood T cells.

Authors:  H Yssel; R De Waal Malefyt; M G Roncarolo; J S Abrams; R Lahesmaa; H Spits; J E de Vries
Journal:  J Immunol       Date:  1992-10-01       Impact factor: 5.422

7.  Differential effect of transforming growth factor beta on the synthesis of Th1- and Th2-like lymphokines by human T lymphocytes.

Authors:  C Fargeas; C Y Wu; T Nakajima; D Cox; T Nutman; G Delespesse
Journal:  Eur J Immunol       Date:  1992-08       Impact factor: 5.532

8.  Functional CD4 T cell subset interplay in an intact immune system.

Authors:  J S Murray; J Madri; T Pasqualini; K Bottomly
Journal:  J Immunol       Date:  1993-05-15       Impact factor: 5.422

9.  Immune response of elderly individuals to a live attenuated varicella vaccine.

Authors:  M J Levin; M Murray; H A Rotbart; G O Zerbe; C J White; A R Hayward
Journal:  J Infect Dis       Date:  1992-08       Impact factor: 5.226

10.  Immune responses to varicella zoster virus infections in healthy children.

Authors:  H A Rotbart; M J Levin; A R Hayward
Journal:  J Infect Dis       Date:  1993-01       Impact factor: 5.226

View more
  15 in total

1.  Influence of systemic immune and cytokine responses during the acute phase of zoster on the development of postherpetic neuralgia.

Authors:  Sheng-mei Zhu; Yong-min Liu; Er-dan An; Qing-lian Chen
Journal:  J Zhejiang Univ Sci B       Date:  2009-08       Impact factor: 3.066

2.  Modulation of major histocompatibility class II protein expression by varicella-zoster virus.

Authors:  A Abendroth; B Slobedman; E Lee; E Mellins; M Wallace; A M Arvin
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

3.  Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus.

Authors:  J G Smith; X Liu; R M Kaufhold; J Clair; M J Caulfield
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

4.  Interleukin-6 and type 1 interferons inhibit varicella zoster virus replication in human neurons.

Authors:  Christina N Como; Catherine M Pearce; Randall J Cohrs; Nicholas L Baird
Journal:  Virology       Date:  2018-07-04       Impact factor: 3.616

5.  Herpes zoster vaccine for the elderly: boosting immunity.

Authors:  Joel V Chua; Wilbur H Chen
Journal:  Aging health       Date:  2010-04-01

Review 6.  Varicella-zoster virus.

Authors:  A M Arvin
Journal:  Clin Microbiol Rev       Date:  1996-07       Impact factor: 26.132

7.  Anti-human cytomegalovirus activity of cytokines produced by CD4+ T-cell clones specifically activated by IE1 peptides in vitro.

Authors:  J L Davignon; P Castanié; J A Yorke; N Gautier; D Clément; C Davrinche
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

8.  Local immune responses and systemic cytokine responses in zoster: relationship to the development of postherpetic neuralgia.

Authors:  M Zak-Prelich; R C McKenzie; A Sysa-Jedrzejowska; M Norval
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330

Review 9.  T-cell immunity to human alphaherpesviruses.

Authors:  Werner J D Ouwendijk; Kerry J Laing; Georges M G M Verjans; David M Koelle
Journal:  Curr Opin Virol       Date:  2013-05-08       Impact factor: 7.090

10.  Persistent high frequencies of varicella-zoster virus ORF4 protein-specific CD4+ T cells after primary infection.

Authors:  Louise Jones; Antony P Black; Gathsaurie N Malavige; Graham S Ogg
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.